Shares of Abbott Laboratories (ABT -0.03%) may be up 10.7% since the start of 2013, but this stock has lagged behind the S&P 500 index and many of its health care peers, including Boston Scientific (BSX 0.48%) and Johnson & Johnson. Abbott's next big catalyst will be its second-quarter results, which are set to be revealed tomorrow morning, but will earnings wow investors, or will they miss estimates and disappoint?
In the following video, health care analyst Max Macaluso explains the three main sections in tomorrow's report that investors should watch. Special attention should be paid to medical device sales, which weighed heavily on Abbott and other companies in this sector last quarter.
